Compounded Tirzepatide Cost in 2026: The Honest Breakdown

Quick Answer

As of September 29, 2026, the Majesta Health Performance plan (compounded tirzepatide injection) is $339 your first month, then $439 per month. The first-month price includes the $20 medical consultation fee, and every month includes the physician review, the medication, shipping, and support. Prices at other US telehealth providers vary with the provider, the dose, and the commitment tier.

Compounded preparations are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any brand-name medication. The active pharmaceutical ingredient meets United States Pharmacopeia (USP) standards. The price reflects ingredient, preparation, and program cost.

Compounded Tirzepatide Pricing in 2026

All prices here are cash prices without insurance, in USD, taken from Majesta Health's own pricing on September 29, 2026. How the telehealth path itself works is set out in how to get tirzepatide.

Other providers price compounded tirzepatide in different structures: some bundle the physician, the medication, and shipping into one number, some charge a membership plus the medication, and some price by commitment tier or by dose. Their prices change often, so this page does not quote them. How several providers publish their prices, each with its source and the date it was read, is compared in compounded GLP-1 prices compared.

For a broader walkthrough of buying compounded tirzepatide online, see our compounded tirzepatide online in 2026 guide.

If an FDA-Approved Product Is an Option for You

FDA-approved tirzepatide is a separate category with its own access routes, and it is worth checking before anything else. Ask your insurer whether an FDA-approved tirzepatide product is on your formulary and what prior authorization requires, and check the manufacturer's own patient programs for current self-pay pricing and eligibility. Those figures change, and the manufacturer is the only reliable source for them. For the FDA-approved tirzepatide product for weight management, our cost guide for that product separates its price routes by presentation and coverage. If a listing offers what it calls a generic version of an approved tirzepatide product, why no approved generic is on the record explains what that description leaves out.

Whichever route is open to you, compare documented all-in monthly totals rather than headline prices.

For more on the medication itself, see our guide to compounded tirzepatide online in 2026.

What the Price Should Include

The headline price is only meaningful if you know what is bundled. A lower headline price that bills consultation, shipping, and refills separately can end up costing more than a higher price with everything included. For renewal and cancellation terms, our questions to ask before paying for a GLP-1 subscription walk through what a provider has to disclose.

Before you compare prices, confirm what a compounded tirzepatide plan includes:

• The compounded tirzepatide medication itself, prepared by a state-licensed compounding pharmacy
• Physician consultation with a US-licensed doctor (any medical consultation fee should be disclosed upfront)
• Discreet shipping in plain packaging
• Messaging or scheduled check-ins with your physician for prescription and side-effect questions
• Whether the monthly price changes when your physician changes the dose
• How cancellation works, and whether any prepaid amount is refunded

What should NOT be hidden in the fine print:

• Separate consultation, lab, refill, or visit fees
• A required multi-month prepay to access the published price
• A required paid coaching tier bundled with the medication
• Dose-related price increases that are not disclosed upfront

What Drives Compounded Pricing

Compounded tirzepatide contains an active pharmaceutical ingredient that meets United States Pharmacopeia (USP) standards. It is not FDA-approved as a final product and is not a generic version of, or interchangeable with, any brand product. Three things shape how compounded pricing is set:

1. Ingredient and preparation. The active pharmaceutical ingredient, the concentration, and the vial size a pharmacy prepares all move the number.
2. Batch size. State-licensed 503A pharmacies compound to individual prescriptions rather than running industrial manufacturing lines.
3. What the plan includes. Some programs bundle the physician consultation, shipping, and follow-up messaging into the monthly figure and some bill them separately, which is the single biggest reason two quoted prices are hard to compare.

The trade-off is real and worth stating plainly: compounded preparations are not FDA-approved as final products. The active ingredient meets United States Pharmacopeia (USP) standards, but the specific compounded formulation has not been reviewed by the FDA the way the brand product has.

Insurance and HSA / FSA Reality (2026)

Commercial insurance almost never covers compounded tirzepatide. Coverage of the brand-name products is variable. Most weight-management-indication coverage requires prior authorization with documented BMI plus comorbidity criteria. Coverage for the diabetes indication is generally broader than coverage for weight management. For a fuller look at coverage, see whether insurance covers compounded GLP-1 medications.

Medicare Part D covers the diabetes indication, and its statutory exclusion still bars a GLP-1 used solely for weight loss. Since July 1, 2026 a temporary federal program, the Medicare GLP-1 Bridge, provides eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs. For eligibility and what beneficiaries pay, see Medicare and GLP-1 coverage in 2026.

Medicaid varies by state. Many state programs cover these medications for diabetes only.

HSA and FSA funds can generally pay for a compounded medication that a licensed clinician prescribes to treat a diagnosed medical condition, because IRS Publication 502 counts prescribed drugs as medical expenses; spending that is merely beneficial to general health does not qualify. That tax rule is only the first check: how your FSA administrator or HSA custodian handles the expense, and whether a provider accepts the card at checkout, are separate questions. Keep your prescription confirmation and an itemized receipt, and see our HSA and FSA guide for the account rules and the records to keep.

Dose and Price: Does the Price Change With the Dose?

Your dose is set by the prescribing clinician, who may change it based on your response and tolerability; the schedule is on the pharmacy label and set by the prescriber.

Providers price dose changes differently, so ask any provider, Majesta included, whether the monthly price changes when the dose changes, and get the answer in writing before you enroll. If a provider's price climbs every time your dose goes up, that is a dose-escalation upcharge, and it can quietly turn a $299 headline into a much higher real cost at maintenance.

Majesta's pricing page lists one first-month price and one ongoing monthly price for each plan and states "No upcharges." For the Performance plan, that is $339 for the first month, which includes the $20 medical consultation fee, then $439 per month, so budget around the $439 ongoing price rather than the first month.

Hidden Fees to Watch For

The published headline is not the real cost if any of these are billed on the side:

• Separate consultation fees charged on top of the plan
• Shipping fees per order
• Refill or visit fees at each renewal
• Lab work fees required before the first fill
• Multi-month prepay required to unlock the lowest advertised price
• Cancellation penalties if you stop early
• Paid coaching tiers bundled in whether you want them or not
• Dose-escalation upcharges when your prescribed dose changes

The honest way to compare two providers is to add up the total first-month cost including any one-time fees, then the total ongoing monthly cost with no commitment. Compare those two numbers, not the marketing headline.

How Majesta Performance Prices It

The Majesta Health Performance plan is compounded tirzepatide injection at a flat, all-in price:

• $339 your first month
• $439 per month after that
• No upcharges, as stated on Majesta's pricing page
• Includes the physician consultation, the compounded medication, discreet shipping, and ongoing physician messaging

Here is the all-in six-month math at Majesta's prices as of September 29, 2026:

Totals assume monthly billing; see each provider's billing policy for cycle details. To compare another provider, add up its documented first-month and ongoing totals the same way, with every fee included; brand-name pricing is published by the manufacturers and depends on coverage.

Why Pricing Should Not Be the Only Factor

Three factors matter as much as price when evaluating any compounded tirzepatide source:

1. Is the prescribing physician real and US-licensed? Cheap sources often skip this. Skipping medical screening is the actual safety risk.
2. Is the dispensing pharmacy named and licensed? Ask which state-licensed pharmacy prepares the medication, then look up that license on the state board of pharmacy's site. A provider that will not name its pharmacy is a red flag.
3. Is ongoing physician access included? Questions about side effects and your prescription come up during treatment, and the prescribing physician is the one who answers them. Without a physician you can message, you handle them alone.

For a fuller checklist, see how to check a compounded tirzepatide vial, pharmacy and prescriber.

The pivotal tirzepatide trial programme studied the FDA-approved product; its results describe that product, not any compounded preparation. That is brand-product trial data, and individual results may vary. No legitimate provider, including Majesta, can promise a specific outcome for you.

The Bottom Line

As of September 29, 2026, compounded tirzepatide at Majesta Health is $339 your first month, then $439 per month, with the $20 medical consultation fee included in the first month; prices at other providers vary. Ask any provider for the documented monthly total in writing, including the consultation, the medication, and shipping, before you commit to anything.

Compounded preparations are not FDA-approved as final products; the active pharmaceutical ingredient meets United States Pharmacopeia (USP) standards.

The number that matters is not the headline. It is the all-in monthly cost at a provider with a real US-licensed physician, a named, state-licensed compounding pharmacy, a written answer on whether the price changes with the dose, and ongoing physician access included.

If you want to find out whether treatment may be appropriate for you, start the medical assessment at /quiz. A US-licensed physician reviews your information and decides whether treatment is appropriate; no prescription is guaranteed.

Related guides

• Compounded tirzepatide online in 2026: the legitimate path
• Compounded semaglutide cost in 2026: the honest breakdown

What the primary sources say

• U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers (accessed September 26, 2026): "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."
• Cornell Law School, Legal Information Institute, 21 U.S.C. 353a, Pharmacy compounding (section 503A of the Federal Food, Drug, and Cosmetic Act) (accessed September 26, 2026): "comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists, and the United States Pharmacopoeia chapter on pharmacy compounding"
• Cornell Law School, Legal Information Institute, 42 U.S.C. 1396r-8(d)(2), drugs that may be excluded from coverage (incorporated into the Medicare Part D definition of covered drugs by 42 U.S.C. 1395w-102(e)(2)(A)) (accessed September 26, 2026): "The following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted: (A) Agents when used for anorexia, weight loss, or weight gain."
• Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge (accessed September 29, 2026): "Starting July 1, 2026, Medicare will begin a short-term demonstration, called the Medicare GLP-1 Bridge, that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs."
• Internal Revenue Service, Publication 502, Medical and Dental Expenses (accessed September 26, 2026): "A prescribed drug is one that requires a prescription by a doctor for its use by an individual."

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Majesta Health prices are as of September 29, 2026 and are subject to change. Individual results may vary.